S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
Investing.com -- DSM-Firmenich AG stock gained 3.3% after the company reported second quarter adjusted EBITDA of €610 million, matching analyst consensus of €609 million, as organic growth and margin improvement offset temporary vitamin headwinds.
The Dutch-Swiss specialty chemicals company posted sales of €3,236 million for the quarter, slightly below the consensus estimate of €3,239 million but representing a 6% organic growth year-over-year, driven by 2% volume growth and 4% price increases.
DSM-Firmenich’s adjusted EBITDA margins improved significantly, rising 300 basis points compared to the same period last year. The company’s organic growth excluding its animal nutrition business was 3.1%, slightly below consensus expectations of 3.4%.
Looking ahead, DSM-Firmenich updated its full-year 2025 adjusted EBITDA guidance to "around €2.4 billion," a slight adjustment from its previous outlook of "at least" €2.4 billion. The current analyst consensus stands at €2.37 billion. The guidance includes a €150 million temporary impact from vitamins, with €125 million of this effect already recorded in the first half of the year.
The company also noted that the divestment of its animal nutrition business is progressing well and entering its final stages, though no specific timeline was provided for completion of the transaction.
All divisions performed broadly in line with expectations during the quarter, contributing to the positive market reaction despite the slight moderation in full-year guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.